Sugi Predict

Sugi Predict / Compounds / SCHEMBL691835

SCHEMBL691835

SCHEMBL691835

O=[C]C1CCc2ccccc2C1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 1/20 0.50
▸ MTNR1A P48039 4/20 0.47
▸ MTNR1B P49286 4/20 0.47
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ ANPEP P15144 4/20 0.43
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ SRD5A1 P18405 1/20 0.40
▸ GRIN2B Q13224 1/20 0.40
▸ HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385635 0.84 IDO1 (0.41) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL9123705 0.79 MAOA (0.50) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL2725956 0.79 CYP1A2 (0.51) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL9125425 0.72 PLAU (0.43) PLAUMTNR1AMTNR1BANPEPMAOA
SCHEMBL277274 0.71 PLAU (0.56) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL7879944 0.71 PLAU (0.45) PLAUMTNR1AMTNR1BANPEPMAOA
SCHEMBL4023875 0.71 PLAU (0.46) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL5693079 0.70 PLAU (0.60) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL388174 0.69 PLAU (0.58) PLAUMTNR1AMTNR1BCA1CA2
SCHEMBL13929740 0.68 PLAU (0.52) PLAUMTNR1AMTNR1BCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043639-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells MOLECULAR TRANSFER, INC. (US) 2024-07-23 — — US disclosed
EP-4384508-A2 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-06-19 — — EP disclosed
WO-2024031051-A1 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-02-08 — — WO disclosed
US-20240000966-A1 Lipid Compositions For In Vivo Delivery Life Technologies Corporation 2024-01-04 — — US disclosed
WO-2024006937-A1 LIPID COMPOSITIONS FOR IN VIVO DELIVERY Life Technologies Corporation (US) 2024-01-04 — — WO disclosed
WO-2023018990-A2 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2023-02-16 — — WO disclosed
US-20210323984-A1 POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. 2021-10-21 — — US disclosed
US-20210189433-A1 AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS Molecular Transfer Inc. 2021-06-24 — — US disclosed
US-10968240-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells MOLECULAR TRANSFER, INC. (US) 2021-04-06 — — US disclosed
US-10883118-B2 Agents for improved delivery of nucleic acids to eukaryotic cells Molecular Transfer Inc. (US) 2021-01-05 — — US disclosed
WO-1994004492-A1 HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1994-03-03 — — WO disclosed
WO-1993023368-A1 UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1993-11-25 — — WO disclosed
WO-1993023379-A1 RETROVIRAL PROTEASE INHIBITORS MONSANTO COMPANY (US) 1993-11-25 — — WO disclosed
EP-0558603-A1 RETROVIRAL PROTEASE INHIBITORS MONSANTO COMPANY (US) 1993-09-08 — — EP disclosed
EP-0558657-A1 RETROVIRAL PROTEASE INHIBITORS. MONSANTO CO (US) 1993-09-08 — — EP disclosed
US-5157041-A Viricides HOFFMANN-LA ROCHE INC. (US) 1992-10-20 — — US disclosed
WO-1992008700-A1 RETROVIRAL PROTEASE INHIBITORS MONSANTO COMPANY (US) 1992-05-29 — — WO disclosed
WO-1992008688-A1 RETROVIRAL PROTEASE INHIBITORS MONSANTO COMPANY (US) 1992-05-29 — — WO disclosed
EP-0432694-A2 Aminoalcohols F. HOFFMANN-LA ROCHE AG (CH) 1991-06-19 — — EP disclosed
EP-0346847-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043639-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells PHOSPHO1, MBOAT7, PLTP PLAU 2558/4885MTNR1A 4065/4885MTNR1B 3978/4885
US-10883118-B2 Agents for improved delivery of nucleic acids to eukaryotic cells SNRPE, POLRMT, PHAX PLAU 2553/4885MTNR1A 4114/4885MTNR1B 4151/4885
US-10968240-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells PHOSPHO1, MBOAT7, PLTP PLAU 2558/4885MTNR1A 4065/4885MTNR1B 3978/4885
US-20240000966-A1 Lipid Compositions For In Vivo Delivery CHMP4B, LIPA, CETP PLAU 2422/4885MTNR1A 3873/4885MTNR1B 3762/4885
US-20210189433-A1 AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS SNRPE, POLRMT, PHAX PLAU 2553/4885MTNR1A 4114/4885MTNR1B 4151/4885
US-20210323984-A1 POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS POLRMT, PHOSPHO1, MBOAT7 PLAU 2873/4885MTNR1A 4098/4885MTNR1B 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.